In this issue:
Drug survival of biologics for psoriasis
New-onset psoriasis associated with TNF-α inhibitor treatment
Anti-rituximab antibodies in patients with pemphigus
Dupilumab in children with moderate-to-severe atopic dermatitis
Baricitinib for alopecia areata
Risk factors for paradoxical eczema with biologics
Risankizumab in psoriasis patients who failed anti-IL-17
Apremilast monotherapy in moderate-to-severe plaque psoriasis
Bimekizumab in moderate-to-severe plaque psoriasis
Nail psoriasis improvement with tildrakizumab
Please login below to download this issue (PDF)